2-甲基-2-丙基{2-[(羟基甲基)氨基]-2-氧代乙基}氨基甲酸酯 | 146540-02-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-甲基-2-丙基{2-[(羟基甲基)氨基]-2-氧代乙基}氨基甲酸酯
• 英文名称: N'-methyl-N-(tert-butoxycarbonyl)glycine hydroxamic acid
• 英文别名: tert-butyl N-[2-[hydroxy(methyl)amino]-2-oxoethyl]carbamate
• CAS: 146540-02-5
• 化学式: C₈H₁₆N₂O₄
• 分子量: 204.226
• InChiKey: RBBSROYJAJGKIK-UHFFFAOYSA-N

物化性质

• 密度：
  1.168±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-甲基-2-丙基{2-[(羟基甲基)氨基]-2-氧代乙基}氨基甲酸酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 生成 2-amino-N-hydroxy-N-methylacetamide
  参考文献：
  名称：

  Modular Fluorescent-Labeled Siderophore Analogues

  摘要：

  Biomimetic analogues 1 of the microbial siderophore (iron carrier) ferrichrome were labeled via piperazine with various fluorescent markers at a site not interfering with iron binding or receptor recognition (compounds 10-12). These iron carriers were built from a tetrahedral carbon symmetrically extended with three strands, each containing an amino acid (G = glycyl, A = alanyl, L = leucyl and P = phenylalanyl) and terminated by a hydroxamic acid, which together define an octahedral iron-binding domain. A fourth exogenous strand provided the site for connecting various fluorescent markers via a short bifunctional linker. Iron(III) titrations, along with fluorescence spectroscopy, generated quenching of fluorescence emission of some of the probes used. The quenching process fits the Perrin model which reinforces the intramolecular quenching process, postulated previously.(1) All tested compounds, regardless of their probe size, polarity, or the linker binding them to the siderophore analogue, promote growth of Pseudomonas putida with the same efficacy as the nonlabeled analogues 1, with the added benefit of signaling microbial activity by fluorescence emission. All G derivatives of compounds 10-12 were found to parallel the behavior of natural ferrichrome, whereas A derivatives mediated only a modest iron(III) uptake by P. putida. Incubation of various Pseudomonas strains with iron(III)-loaded G derivatives resulted in the build-up of the labels' fluorescence in the culture medium to a much larger extent than from the corresponding A derivatives. The fluorescence buildup corresponds to iron utilization by the cells and the release of the fluorescent labeled desferrisiderophore from the cell to the media. The fact that the microbial activity of these compounds is not altered by attachment of various fluorescent markers via a bifunctional linker proposes their application as diagnostic tools for detecting and identifying pathogenic microorganisms.

  DOI：

  10.1021/jm970581b
• 作为产物：
  描述：

  BOC-甘氨酸 、 N-甲基羟胺 在 N,N'-羰基二咪唑 作用下， 生成 2-甲基-2-丙基{2-[(羟基甲基)氨基]-2-氧代乙基}氨基甲酸酯
  参考文献：
  名称：

  Johnson; Boxer; Drummond, Arzneimittel-Forschung/Drug Research, 1989, vol. 39, # 4, p. 432 - 437

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS<br/>[FR] HYDANTOÏNAMIDES SUBSTITUÉS UTILISÉS EN TANT QU'ANTAGONISTES D'ADAMTS7
  申请人：BAYER AG

  公开号：WO2021094436A1

  公开（公告）日：2021-05-20

  The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty. R1 is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, heteroaryl or phenyl; R2 is hydrogen, cyano, halogen, alkylsulfonyl, alkyl, cycloalkyl or alkoxy; R3, R4, R5, R6, R7 and R8 are independently hydrogen, halogen, alkyl or alkoxy; most groups being optionally substituted; with the proviso that at least one of R2, R3, R4 is H; X1, X2, X3, X4, X5 and X6 are independently N or C; with the proviso that in each ring maximal one X is N.

  本申请涉及式(I)所示的取代脒酰胺作为ADAMTS7拮抗剂，涉及它们的制备过程，以及它们单独或组合用于治疗或预防疾病，特别是心血管疾病，包括动脉粥样硬化、冠心病(CAD)、外周血管病(PAD)、动脉闭塞性疾病或血管成形术后的再狭窄。R1是氢、烷基、环烷基、杂环烷基、杂芳基或苯基；R2是氢、氰基、卤素、烷基亚磺酰基、烷基、环烷基或烷氧基；R3、R4、R5、R6、R7和R8独立的是氢、卤素、烷基或烷氧基；大多数基团可被选择性地取代；条件是至少R2、R3、R4中的一个为H；X1、X2、X3、X4、X5和X6独立的是N或C；条件是每个环中最多只有一个X是N。
• Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine
  申请人：Kohn Harold

  公开号：US20080249181A1

  公开（公告）日：2008-10-09

  Antimycorbacterial compositions are disclosed comprising at least one hydroxamate or at least one hydroxamate and at least one hydroxylamine. The preferred ratio of hydroxamate to hydroxylamines is about 100:1 to about 1:1. A method for inhibiting mycobacterial growth is also disclosed comprising the step of administering the compositions of this invention to an animal including a human.

  公开了包含至少一种羟肟酸盐或至少一种羟肟酸盐和至少一种羟肟胺的抗分枝杆菌组合物。羟肟酸盐与羟肟胺的优选比例约为100：1至约1：1。还公开了一种抑制分枝杆菌生长的方法，包括将本发明的组合物给动物，包括人类。
• Receptor antagonists
  申请人：Proximagen Limited

  公开号：EP2927224A1

  公开（公告）日：2015-10-07

  The compounds of formula (I) are antagonists of the CXCR4 receptor Wherein R1, X, Y and R2 are as defined in the claims.

  式（I）化合物是 CXCR4 受体的拮抗剂 其中 R1、X、Y 和 R2 如权利要求中所定义。
• [EN] COMPOSITIONS HAVING ANTIMYCROBIAL ACTIVITY INCLUDING A HYDROXAMATE OR A HYDROXAMATE AND A HYDROXYLAMINE<br/>[FR] COMPOSITIONS A ACTIVITE ANTIMYCOBACTERIENNE COMPRENANT UN HYDROXAMATE OU UN HYDROXAMATE ET UNE HYDROXYLAMINE
  申请人：UNIV HOUSTON SYSTEM

  公开号：WO2005020973A3

  公开（公告）日：2005-04-07
• US7662856B2
  申请人：——

  公开号：US7662856B2

  公开（公告）日：2010-02-16